| 04/29/2026 4:30 PM | Janux Therapeutics (1817713) Subject Point72 Asset Management, L.P. (1603466) Filed by | Form SCHEDULE 13G | |
| 04/29/2026 4:31 PM | Janux Therapeutics (1817713) Subject Point72 Asset Management, L.P. (1603466) Filed by | Form SCHEDULE 13G | |
| 04/28/2026 3:56 PM | Janux Therapeutics (1817713) Filer | Form ARS | |
| 04/28/2026 4:02 PM | Janux Therapeutics (1817713) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 04/28/2026 3:15 PM | Janux Therapeutics (1817713) Filer | Form DEF 14A | |
| 04/13/2026 3:05 PM | Janux Therapeutics (1817713) Subject Meyer Andrew Hollman (1864159) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 02/26/2026 3:47 PM | Janux Therapeutics (1817713) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 02/26/2026 3:32 PM | Janux Therapeutics (1817713) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 02/26/2026 3:10 PM | Janux Therapeutics (1817713) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 02/09/2026 5:43 AM | Janux Therapeutics (1817713) Subject STATE STREET CORP (93751) Filed by STATE STREET CORP (93751) Filed by | Form SCHEDULE 13G | |
| 02/06/2026 3:23 PM | Janux Therapeutics (1817713) Subject Prosight Management, LP (1617201) Filed by | Form SCHEDULE 13G | |
Get the Latest News and Ratings for JANX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Janux Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 02/04/2026 7:00 PM | Go William (2108554) Reporting Janux Therapeutics (1817713) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 02/04/2026 7:01 PM | Go William (2108554) Reporting Janux Therapeutics (1817713) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/23/2026 3:08 PM | Janux Therapeutics (1817713) Subject Meyer Andrew Hollman (1864159) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/22/2026 3:30 PM | Janux Therapeutics (1817713) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/08/2026 8:09 AM | FMR LLC (315066) Filed by Janux Therapeutics (1817713) Subject | Form SCHEDULE 13G/A | |
| 01/02/2026 8:00 PM | Dobek Maria (2032671) Reporting Janux Therapeutics (1817713) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/02/2026 8:00 PM | Doyle Janeen Noel (2069239) Reporting Janux Therapeutics (1817713) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/02/2026 8:00 PM | Janux Therapeutics (1817713) Issuer McIver Zachariah (2050056) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/02/2026 8:00 PM | Janux Therapeutics (1817713) Issuer Winter Charles M. (1960264) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/02/2026 8:00 PM | Campbell David Alan (1864158) Reporting Janux Therapeutics (1817713) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/02/2026 8:00 PM | DiRaimondo Thomas (2005618) Reporting Janux Therapeutics (1817713) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/02/2026 8:00 PM | Janux Therapeutics (1817713) Issuer Meyer Andrew Hollman (1864159) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/08/2025 3:42 PM | Janux Therapeutics (1817713) Subject Robinson Byron (1914899) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/03/2025 7:00 PM | Janux Therapeutics (1817713) Issuer Meyer Andrew Hollman (1864159) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/02/2025 4:15 PM | Janux Therapeutics (1817713) Subject Robinson Byron (1914899) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/01/2025 3:20 PM | Janux Therapeutics (1817713) Subject Meyer Andrew Hollman (1864159) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/14/2025 7:00 PM | Janux Therapeutics (1817713) Issuer Meyer Andrew Hollman (1864159) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/07/2025 11:10 AM | JANUS HENDERSON GROUP PLC (1274173) Filed by Janux Therapeutics (1817713) Subject | Form SCHEDULE 13G/A | |
| 11/06/2025 3:39 PM | Janux Therapeutics (1817713) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 11/06/2025 3:10 PM | Janux Therapeutics (1817713) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/30/2025 7:00 PM | Janux Therapeutics (1817713) Issuer Meyer Andrew Hollman (1864159) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/28/2025 3:16 PM | Janux Therapeutics (1817713) Subject Meyer Andrew Hollman (1864159) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 09/19/2025 4:06 PM | Janux Therapeutics (1817713) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/14/2025 10:26 AM | JANUS HENDERSON GROUP PLC (1274173) Filed by Janux Therapeutics (1817713) Subject | Form SCHEDULE 13G/A | |
| 08/12/2025 8:05 AM | Adage Capital Management, L.P. (1535978) Filed by Janux Therapeutics (1817713) Subject | Form SCHEDULE 13G/A | |
| 07/17/2025 6:54 PM | BlackRock, Inc. (2012383) Filed by Janux Therapeutics (1817713) Subject | Form SCHEDULE 13G | |
| 06/13/2025 6:30 PM | Janux Therapeutics (1817713) Issuer Kung Winston (1666963) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/13/2025 6:30 PM | Janux Therapeutics (1817713) Issuer Simson Jake (1863094) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/13/2025 6:30 PM | Janux Therapeutics (1817713) Issuer McNulty Alana B. (1606086) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/13/2025 6:30 PM | Hernday Natasha (1780547) Reporting Janux Therapeutics (1817713) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
|
| 06/13/2025 6:30 PM | Gujrathi Sheila (1575202) Reporting Janux Therapeutics (1817713) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/13/2025 6:30 PM | DOBMEIER ERIC (1202785) Reporting Janux Therapeutics (1817713) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/13/2025 6:30 PM | CAPPS VICKIE L (1248190) Reporting Janux Therapeutics (1817713) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/13/2025 6:30 PM | Barrett Ronald W (1326330) Reporting Janux Therapeutics (1817713) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/13/2025 6:33 PM | Janux Therapeutics (1817713) Issuer Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting RA Capital Nexus Fund II, L.P. (1825376) Reporting Shah Rajeev M. (1619841) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/04/2025 7:00 PM | Doyle Janeen Noel (2069239) Reporting Janux Therapeutics (1817713) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/23/2025 7:02 PM | Doyle Janeen Noel (2069239) Reporting Janux Therapeutics (1817713) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 05/14/2025 11:25 AM | JANUS HENDERSON GROUP PLC (1274173) Filed by Janux Therapeutics (1817713) Subject | Form SCHEDULE 13G/A | |
| 05/08/2025 3:30 PM | Janux Therapeutics (1817713) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |